Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads

Screening North American plant extracts in vitro against Trypanosoma brucei for discovery of new antitrypanosomal drug leads

(2016) Surendra Jain et al.   BMC Complementary and Alternative Medicine

Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines

(2014) Sudhakar Manda et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

p53 as a target for the treatment of cancer

(2014) Michael J. Duffy et al.   CANCER TREATMENT REVIEWS

Targeting apicoplasts in malaria parasites

(2012) Christopher D Goodman et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Characterization of the Ubiquitylating Components of the Human Malaria Parasite’s Protein Degradation Pathway

(2012) Duk-Won D. Chung et al.   PLoS One

Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts

(2011) Cyrus Chargari et al.   CANCER LETTERS

Unraveling the Ubiquitome of the Human Malaria Parasite

(2011) Nadia Ponts et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage

(2010) Xing Zeng et al.   CANCER CELL

Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase

(2010) Mariam Aghajan et al.   NATURE BIOTECHNOLOGY

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2

(2008) J. Kitagaki et al.   MOLECULAR CANCER THERAPEUTICS

Deciphering the Ubiquitin-Mediated Pathway in Apicomplexan Parasites: A Potential Strategy to Interfere with Parasite Virulence

(2008) Nadia Ponts et al.   PLoS One

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA